Ahmedabad-based Zydus Cadila will become the first company to launch H1N1 (swine flu) vaccine in India.
The company has received an approval from the Drug Controller General of India (DCGI) to market the ‘vaxiflu-s’ vaccine. Buoyed with success in swine flu vaccine, the company, which had a turnover of Rs 3,687 crore in 2009-10, will invest Rs 500 crore in 3-4 years to develop vaccines against bacterial, viral and protozoal infections.
“With the development and launch of vaxiflu-s, Zydus now has proven capabilities in researching, developing, and manufacturing of safe and efficacious vaccines,” said Pankaj Patel, chairman and managing director of Zydus Cadila.
The egg based, inactivated vaccine has been developed at company’s Vaccine Technology Centre in Ahmedabad.
The vaccine, which will be marketed under the brand name vaxiflu-s, is expected to be available in the market by the end of this month.
The company aims to sell around 2 million in the current financial year in the Indian market that has potential of 4- 5 million doses per annum.